



(51) International Patent Classification:

C12Q 1/6886 (2018.01) C12Q 1/68 (2018.01)

C12Q 1/6874 (2018.01) G16B 40/00 (2019.01)

C12Q 1/6869 (2018.01)

(21) International Application Number:

PCT/US2023/022104

(22) International Filing Date:

12 May 2023 (12.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/341,323 12 May 2022 (12.05.2022) US

(71) Applicant: DELFI DIAGNOSTICS, INC. [US/US]; 2809

Boston Street, Suite 503, Baltimore, Maryland 21224 (US).

(72) Inventors: BACH, Peter; c/o Delfi Diagnostics, Inc.,

2809 Boston Street, Suite 503, Baltimore, Maryland 21224

(US). MADDALA, Tara; c/o Delfi Diagnostics, Inc., 2809

Boston Street, Suite 503, Baltimore, Maryland 21224 (US).

LEAL, Alessandro; c/o Delfi Diagnostics, Inc., 2809

Boston Street, Suite 503, Baltimore, Maryland 21224 (US).

JAKUBOWSKI, Debbie; c/o Delfi Diagnostics, Inc., 2809

Boston Street, Suite 503, Baltimore, Maryland 21224 (US).

WU, Tony; c/o Delfi Diagnostics, Inc., 2809 Boston Street,

Suite 503, Baltimore, Maryland 21224 (US).

(74) Agent: HAILE, Lisa, A. et al.; DLA Piper LLP US,

4365 Executive Drive, Suite 1100, San Diego, California

92121-2133 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: USE OF CELL-FREE DNA FRAGMENTOMES IN THE DIAGNOSTIC EVALUATION OF PATIENTS WITH SIGNS AND SYMPTOMS SUGGESTIVE OF CANCER




FIGURE 1

(57) Abstract: The present disclosure provides methods of uses thereof for improved diagnostic applications using genome-wide patterns of fragmented cell-free DNA (cfDNA) from plasma, derived by low-coverage whole-genome sequencing, and analyzed in conjunction with certain clinical and demographic features of individual patients. In particular, the present invention provides new and effective methods for confirming the presence or absence of cancer in an individual patient already suspected of having cancer.

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*